CN103582642B - Hsp90抑制剂 - Google Patents
Hsp90抑制剂 Download PDFInfo
- Publication number
- CN103582642B CN103582642B CN201280027256.0A CN201280027256A CN103582642B CN 103582642 B CN103582642 B CN 103582642B CN 201280027256 A CN201280027256 A CN 201280027256A CN 103582642 B CN103582642 B CN 103582642B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- group
- alkynyl
- another embodiment
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161472061P | 2011-04-05 | 2011-04-05 | |
| US61/472,061 | 2011-04-05 | ||
| PCT/US2012/032371 WO2012138894A1 (en) | 2011-04-05 | 2012-04-05 | Hsp90 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103582642A CN103582642A (zh) | 2014-02-12 |
| CN103582642B true CN103582642B (zh) | 2021-05-11 |
Family
ID=48166734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280027256.0A Expired - Fee Related CN103582642B (zh) | 2011-04-05 | 2012-04-05 | Hsp90抑制剂 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9346808B2 (https=) |
| EP (1) | EP2694505B1 (https=) |
| JP (1) | JP6266506B2 (https=) |
| KR (1) | KR102010222B1 (https=) |
| CN (1) | CN103582642B (https=) |
| AU (1) | AU2012240077C1 (https=) |
| BR (1) | BR112013025634A2 (https=) |
| CA (1) | CA2832530C (https=) |
| EA (1) | EA201391334A1 (https=) |
| MX (1) | MX360390B (https=) |
| WO (1) | WO2012138894A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7834181B2 (en) | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| US9403828B2 (en) | 2005-02-01 | 2016-08-02 | Sloan-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| US10336757B2 (en) | 2006-06-30 | 2019-07-02 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases through inhibition of HSP90 |
| WO2011044394A1 (en) | 2009-10-07 | 2011-04-14 | Sloan-Kettering Institute For Cancer Research | Purine derivatives useful as hsp90 inhibitors |
| WO2012138894A1 (en) | 2011-04-05 | 2012-10-11 | Sloan-Kettering Institute For Cancer Research | Hsp90 inhibitors |
| ES2647889T3 (es) | 2011-04-05 | 2017-12-27 | Sloan-Kettering Institute For Cancer Research | Inhibidores de la Hsp90 |
| DK2729806T3 (en) * | 2011-07-08 | 2017-05-15 | Sloan-Kettering Inst For Cancer Res | APPLICATIONS OF MARKED HSP90 INHIBITORS |
| US10201623B2 (en) | 2013-03-15 | 2019-02-12 | Memorial Sloan Kettering Cancer Center | HSP90-targeted cardiac imaging and therapy |
| JP6539275B2 (ja) | 2013-08-16 | 2019-07-03 | メモリアル スローン ケタリング キャンサー センター | 選択的ｇｒｐ９４阻害剤およびその使用 |
| MX2016008418A (es) * | 2013-12-23 | 2017-01-11 | Memorial Sloan Kettering Cancer Center | Metodos y reactivos para el radiomarcaje. |
| CN113521314A (zh) | 2014-09-17 | 2021-10-22 | 纪念斯隆-凯特琳癌症中心 | Hsp90-靶向炎症和感染成像及治疗 |
| US10118890B2 (en) | 2014-10-10 | 2018-11-06 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
| WO2017062520A1 (en) | 2015-10-05 | 2017-04-13 | Memorial Sloan Kettering Cancer Center | Rational combination therapy for the treatment of cancer |
| KR20200019220A (ko) * | 2017-06-23 | 2020-02-21 | 사무스 테라퓨틱스, 인코포레이티드 | 외상성 뇌 손상 및 이의 후유증에 대한 에피샤페롬 저해제 치료법 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200838863A (en) * | 2007-03-20 | 2008-10-01 | Curis Inc | HSP90 inhibitors containing a zinc binding moiety |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2287387C (en) | 1997-05-14 | 2010-02-16 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for destruction of selected proteins |
| WO2000061578A1 (en) | 1999-04-09 | 2000-10-19 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases |
| JP2005519848A (ja) | 2000-11-02 | 2005-07-07 | スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ | Ｈｓｐ９０に結合するための小分子組成物 |
| BR0210391A (pt) | 2001-06-12 | 2004-06-15 | Elan Pharm Inc | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto |
| US7241890B2 (en) | 2001-10-30 | 2007-07-10 | Conforma Therapeutics Corporation | Purine analogs having HSP90-inhibiting activity |
| WO2003041643A2 (en) | 2001-11-09 | 2003-05-22 | Conforma Therapeutics Corporation | Hsp90-inhibiting zearalanol compounds and methods of producing and using same |
| JP2005524661A (ja) | 2002-02-28 | 2005-08-18 | アストラゼネカ アクチボラグ | ３−シクリル−５−（窒素含有５員環）メチル−オキサゾリジノン誘導体と抗菌剤としてのその使用 |
| WO2004094647A2 (en) | 2003-04-18 | 2004-11-04 | Cytovia, Inc. | Methods of treating diseases responsive to induction of apoptosis and screening assays |
| KR20060070572A (ko) | 2003-09-18 | 2006-06-23 | 콘포마 세러퓨틱스 코포레이션 | Ｈｓｐ90-저해제로서의 신규 헤테로시클릭 화합물 |
| US7834181B2 (en) | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| US9403828B2 (en) | 2005-02-01 | 2016-08-02 | Sloan-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| EP1962863A4 (en) * | 2005-12-22 | 2010-11-24 | Conforma Therapeutics Corp | ORALLY ACTIVE PURINE INHIBITORS OF THERMAL SHOCK PROTEIN 90 |
| WO2007134298A2 (en) | 2006-05-12 | 2007-11-22 | Myriad Genetics, Inc. | Therapeutic compounds and their use in cancer |
| US10336757B2 (en) | 2006-06-30 | 2019-07-02 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases through inhibition of HSP90 |
| EP2061772A4 (en) | 2006-09-11 | 2011-06-29 | Curis Inc | MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES |
| FR2906824B1 (fr) | 2006-10-09 | 2008-12-26 | Roger Mondelin Sas Soc Par Act | Dispositif support de butees pour la pose de plaques de platre de largeur variable avec des appareils de levage et de manutention desdites plaques |
| CL2007002994A1 (es) * | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| GB0622084D0 (en) | 2006-11-06 | 2006-12-13 | Chroma Therapeutics Ltd | Inhibitors of HSP90 |
| JP5401329B2 (ja) * | 2007-03-20 | 2014-01-29 | キュリス，インコーポレイテッド | Ｈｓｐ９０インヒビターとしての縮合アミノピリジン |
| EP2183221A1 (en) * | 2007-07-12 | 2010-05-12 | Crystax Pharmaceuticals S.L. | New compounds as hsp90 inhibitors |
| WO2009042646A1 (en) | 2007-09-24 | 2009-04-02 | Curis, Inc. | Anti-proliferative agents |
| CA2705579A1 (en) * | 2007-11-14 | 2009-05-22 | Myriad Pharmaceuticals, Inc. | Therapeutic compounds and their use in treating diseases and disorders |
| CA2786715C (en) | 2009-01-16 | 2019-05-21 | Curis, Inc. | Fused amino pyridines for the treatment of brain tumors |
| GB0905328D0 (en) * | 2009-03-27 | 2009-05-13 | Ge Healthcare Ltd | Indole derivatives |
| CN102781520B (zh) * | 2009-07-17 | 2016-06-08 | 帕夫泰克技术私人有限公司 | 呼吸器 |
| GB0914543D0 (en) * | 2009-08-20 | 2009-09-30 | Ge Healthcare Ltd | Radioiodination method |
| WO2011044394A1 (en) | 2009-10-07 | 2011-04-14 | Sloan-Kettering Institute For Cancer Research | Purine derivatives useful as hsp90 inhibitors |
| ES2647889T3 (es) | 2011-04-05 | 2017-12-27 | Sloan-Kettering Institute For Cancer Research | Inhibidores de la Hsp90 |
| WO2012138894A1 (en) | 2011-04-05 | 2012-10-11 | Sloan-Kettering Institute For Cancer Research | Hsp90 inhibitors |
| JP6539275B2 (ja) | 2013-08-16 | 2019-07-03 | メモリアル スローン ケタリング キャンサー センター | 選択的ｇｒｐ９４阻害剤およびその使用 |
-
2012
- 2012-04-05 WO PCT/US2012/032371 patent/WO2012138894A1/en not_active Ceased
- 2012-04-05 CA CA2832530A patent/CA2832530C/en active Active
- 2012-04-05 US US14/009,976 patent/US9346808B2/en active Active
- 2012-04-05 EP EP12717520.6A patent/EP2694505B1/en active Active
- 2012-04-05 AU AU2012240077A patent/AU2012240077C1/en not_active Ceased
- 2012-04-05 EA EA201391334A patent/EA201391334A1/ru unknown
- 2012-04-05 MX MX2013011532A patent/MX360390B/es active IP Right Grant
- 2012-04-05 KR KR1020137029259A patent/KR102010222B1/ko not_active Expired - Fee Related
- 2012-04-05 BR BR112013025634A patent/BR112013025634A2/pt not_active IP Right Cessation
- 2012-04-05 CN CN201280027256.0A patent/CN103582642B/zh not_active Expired - Fee Related
- 2012-04-05 JP JP2014503994A patent/JP6266506B2/ja not_active Expired - Fee Related
-
2016
- 2016-05-20 US US15/160,293 patent/US9926321B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200838863A (en) * | 2007-03-20 | 2008-10-01 | Curis Inc | HSP90 inhibitors containing a zinc binding moiety |
Non-Patent Citations (2)
| Title |
|---|
| RN 1061319-15-0;REGISTRY;《STN Columbus》;20081014;第2页 * |
| RN 1061319-17-2;REGISTRY;《STN Columbus》;20081014;第2页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20140088121A1 (en) | 2014-03-27 |
| AU2012240077A1 (en) | 2013-10-31 |
| US9346808B2 (en) | 2016-05-24 |
| EP2694505B1 (en) | 2022-04-27 |
| MX360390B (es) | 2018-10-31 |
| EP2694505A1 (en) | 2014-02-12 |
| AU2012240077C1 (en) | 2017-08-10 |
| CA2832530C (en) | 2021-02-16 |
| EA201391334A1 (ru) | 2014-06-30 |
| BR112013025634A2 (pt) | 2016-07-19 |
| US9926321B2 (en) | 2018-03-27 |
| JP2014510148A (ja) | 2014-04-24 |
| CN103582642A (zh) | 2014-02-12 |
| WO2012138894A4 (en) | 2012-12-06 |
| AU2012240077B2 (en) | 2017-04-20 |
| KR102010222B1 (ko) | 2019-08-13 |
| WO2012138894A1 (en) | 2012-10-11 |
| US20160264577A1 (en) | 2016-09-15 |
| KR20140062429A (ko) | 2014-05-23 |
| CA2832530A1 (en) | 2012-10-11 |
| NZ616758A (en) | 2016-01-29 |
| MX2013011532A (es) | 2014-08-22 |
| JP6266506B2 (ja) | 2018-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103582642B (zh) | Hsp90抑制剂 | |
| US10064867B2 (en) | Hsp90 inhibitors | |
| KR102089234B1 (ko) | Ask1 억제제로서의 피리딘 유도체 및 이의 제조방법과 용도 | |
| CA3077267A1 (en) | Fused heteroaryl ring derivatives useful as a2a receptor inhibitor | |
| CA3201054A1 (en) | Novel compounds as androgen receptor and phosphodiesterase dual inhibitor | |
| HK1194376A (en) | Hsp90 inhibitors | |
| HK1194376B (en) | Hsp90 inhibitors | |
| JP2017061540A (ja) | Ｈｓｐ９０阻害物質 | |
| HK1194375A (en) | Hsp90 inhibitors | |
| HK1194375B (en) | Hsp90 inhibitors | |
| NZ616758B2 (en) | Hsp90 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210511 |